CYSLTR1 and myeloid sarcoma: With relevance to MS, MTK administration in mice reduced CysLTR1 mediated effects such as CNS infiltration of inflammatory cells such as Th1 and Th17, demyelination, BBB permeability, and clinical symptoms associated with EAE.